杨洁, 王晓明. 非维生素K拮抗剂口服抗凝药治疗房颤的新进展[J]. 心脏杂志, 2019, 31(5): 597-601. DOI: 10.12125/j.chj.201905043
    引用本文: 杨洁, 王晓明. 非维生素K拮抗剂口服抗凝药治疗房颤的新进展[J]. 心脏杂志, 2019, 31(5): 597-601. DOI: 10.12125/j.chj.201905043
    Jie YANG, Xiao-ming WANG. Research progress of non-vitamin K antagonist oral anticoagulants in treatment of patients with atrial fibrillation[J]. Chinese Heart Journal, 2019, 31(5): 597-601. DOI: 10.12125/j.chj.201905043
    Citation: Jie YANG, Xiao-ming WANG. Research progress of non-vitamin K antagonist oral anticoagulants in treatment of patients with atrial fibrillation[J]. Chinese Heart Journal, 2019, 31(5): 597-601. DOI: 10.12125/j.chj.201905043

    非维生素K拮抗剂口服抗凝药治疗房颤的新进展

    Research progress of non-vitamin K antagonist oral anticoagulants in treatment of patients with atrial fibrillation

    • 摘要: 房颤(atrial fibrillation,AF)是临床上最常见的一种快速心律失常,可引起血栓栓塞,脑卒中等严重并发症,这也是导致患者致残、致死的直接原因。因此,抗凝预防血栓治疗是目前国际公认的主要措施。华法林作为传统口服抗凝药物,其有效性和安全性都得到了公认,但因其治疗窗窄,需频繁监测等诸多不足限制了临床应用,影响了医患双方的信心。非维生素K拮抗剂口服抗凝药(non-vitamin K antagonist oral anticoagulants,NOACs),主要包括凝血酶抑制剂(达比加群酯)和凝血因子Ⅹa抑制剂(利伐沙班、阿哌沙班和依度沙班),近年来新的研究证据支持其为AF初始抗凝治疗的优先选择。本文将就NOACs的药物特性及在AF患者治疗中的研究进展作一综述。

       

      Abstract: Atrial fibrillation (AF) is one of the most common rapid arrhythmias in clinical practice and it can bring about thromboembolism, stroke and other serious complications, which can be the direct causes of disability and death of patients. Therefore, prevention of thrombosis is currently the main recognized measure internationally. Warfarin, as a traditional oral anticoagulant, has been recognized for its efficacy and safety. However, its narrow therapeutic window, frequent monitoring and other deficiencies of Warfarin have limited its clinical application and the popularity among both doctors and patients. Non-vitamin K antagonist oral anticoagulants (NOACs), mainly including thrombin inhibitor (dabigatran etexilate) and blood coagulation factor X inhibitors (rivaroxaban, apixaban, edoxaban) have been used as the preferred initial anticoagulant therapy for atrial fibrillation in recent years. In this article we provide a brief overview of the drug characteristics of NOACs and research progress of NOACs in the treatment of AF patients.

       

    /

    返回文章
    返回